Chargement en cours...
HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation
Increasing fetal hemoglobin (HbF) provides clinical benefit in patients with sickle cell disease (SCD). We recently identified heme-regulated inhibitor (HRI, EIF2AK1), as a novel HbF regulator. Because HRI is an erythroid-specific protein kinase, it presents a potential target for pharmacologic inte...
Enregistré dans:
| Publié dans: | Blood Adv |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
American Society of Hematology
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7509868/ https://ncbi.nlm.nih.gov/pubmed/32956454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020002475 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|